2017
DOI: 10.3233/jad-170382
|View full text |Cite
|
Sign up to set email alerts
|

Transcranial Sonography in Neurodegenerative Diseases with Cognitive Decline

Abstract: Transcranial sonography (TCS) of the brain parenchyma detects alterations in the substantia nigra (SN), raphe nuclei and basal ganglia; this technique has been established as a tool for the early diagnosis of Parkinson's disease and differential diagnosis from atypical parkinsonian syndromes. Here, we aimed to review the main applications of TCS in neurodegenerative diseases presenting with dementia syndrome, focusing on Alzheimer's disease (AD), dementia with Lewy bodies (DLB), frontotemporal lobar degenerati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 74 publications
0
2
0
Order By: Relevance
“…Early non-invasive examination tools such as transcranial sonography (Favaretto et al, 2018) have been improved, and functional neuroimaging techniques have been gradually applied in AD research (Dennis and Thompson, 2014; delEtoile and Adeli, 2017). The overarching goals of AD research are to determine when and how interventions can slow or stop cognitive decline in patients, and to identify early signs of decline and treatment response.…”
Section: Discussionmentioning
confidence: 99%
“…Early non-invasive examination tools such as transcranial sonography (Favaretto et al, 2018) have been improved, and functional neuroimaging techniques have been gradually applied in AD research (Dennis and Thompson, 2014; delEtoile and Adeli, 2017). The overarching goals of AD research are to determine when and how interventions can slow or stop cognitive decline in patients, and to identify early signs of decline and treatment response.…”
Section: Discussionmentioning
confidence: 99%
“…About 90% of patients with idiopathic Parkinson’s disease (PD) show increased echogenicity of substantia nigra (SN). 1 - 3 SN hyperechogenicity is also demonstrated in genetic forms of PD, including the ones with mutation in Parkin (PARK2), phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1 or PARK6), leucine-rich repeat kinase 2 (LRRK2 or PARK8), and glucocerebrosidase (GBA). 1 , 2 The degree of SN hyperechogenicity in genetic forms resembles those of sporadic ones.…”
Section: Introductionmentioning
confidence: 99%